Investor Alert: Kaplan Fox Announces Investigation Of Akorn, Inc.

NEW YORK, Feb. 27, 2018 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating Akorn, Inc. ("Akorn" or the "Company") (NASDAQ: AKRX), a specialty generic pharmaceutical company, concerning potential securities law violations.  Investors who purchased Akorn securities may be affected.

On April 7, 2017, Akorn confirmed that the Company was in discussions with Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA ("Fresenius"), regarding a potential acquisition of Akorn.  Following this news, Akorn's shares increased in price by over 18%, $4.55 per share, to close at $29.77 per share on April 7, 2017. 

On February 26, 2018, after the market closed, Fresenius, which had been expected to close the acquisition of Akorn in the coming weeks, announced that it is "conducting an independent investigation, using external experts, into alleged breaches of FDA data integrity requirements relating to product development at Akorn, Inc."

On February 27, 2018, following the above disclosures, Akorn's shares plummeted in midday trading by over $10 per share, or about 34%, on heavy trading volume.

If you are an investor in Akorn and would like to discuss our investigation, please contact us by emailing [email protected] or by calling 800-290-1952.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.  If you have any questions about this Notice, the action, your rights, or your interests, please contact:

Frederic S. Fox
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
(800) 290-1952
(212) 687-1980
Fax: (212) 687-7714
E-mail: [email protected]

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
350 Sansome Street, Suite 400
San Francisco, California  94104
(415) 772-4700
Fax:  (415) 772-4707
E-mail: [email protected]

SOURCE Kaplan Fox & Kilsheimer LLP

Related Links

http://www.kaplanfox.com